Sugi Predict

Sugi Predict / Compounds / SCHEMBL4331848

SCHEMBL4331848

SCHEMBL4331848

O=C1CCC(c2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 1/20 0.56
▸ ESR2 Q92731 2/20 0.51
▸ HRH3 Q9Y5N1 2/20 0.51
▸ MAOB P27338 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ LMNA P02545 2/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ TNKS2 Q9H2K2 1/20 0.49
▸ GSTP1 P09211 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ SLC6A2 P23975 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ LIPG Q9Y5X9 1/20 0.48
▸ NR4A1 P22736 1/20 0.47
▸ NR4A2 P43354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24798064 0.91 MRGPRX4 (0.50) MRGPRX4MAOBTP53LMNAKCNH2
SCHEMBL2150597 0.91 MRGPRX4 (0.50) MRGPRX4MAOBTP53LMNAKCNH2
SCHEMBL2149901 0.91 MRGPRX4 (0.50) MRGPRX4MAOBTP53LMNAKCNH2
SCHEMBL10272647 0.87 MRGPRX4 (0.64) MRGPRX4MAOBLMNAKCNH2CYP1A2
SCHEMBL15639718 0.85 MRGPRX4 (0.52) MRGPRX4ESR2HRH3MAOBTP53
SCHEMBL3542422 0.83 CYP3A4 (0.48) MRGPRX4HRH3MAOBTP53LMNA
SCHEMBL5249481 0.83 HRH3 (0.60) MRGPRX4HRH3MAOBLMNAKCNH2
SCHEMBL16969436 0.82 ESR2 (0.57) MRGPRX4ESR2HRH3MAOBTP53
SCHEMBL27853765 0.81 MRGPRX4 (0.58) MRGPRX4HRH3MAOBLMNAKCNH2
SCHEMBL5689614 0.81 TP53 (0.47) MRGPRX4MAOBTP53LMNAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106892805-B Synthesis method of 4- (4-hydroxyphenyl) cyclohexanone 西安瑞联新材料股份有限公司 2021-02-23 — — CN claimed
US-20260055057-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2026-02-26 — — US disclosed
WO-2026042018-A1 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES PFIZER INC. (US) 2026-02-26 — — WO disclosed
CN-107674013-B Polycyclic compound, preparation method, pharmaceutical composition and application thereof 上海迪诺医药科技有限公司 2022-05-24 — — CN disclosed
CN-106892805-B Synthesis method of 4- (4-hydroxyphenyl) cyclohexanone 西安瑞联新材料股份有限公司 2021-02-23 — — CN disclosed
CN-106892805-B Synthesis method of 4- (4-hydroxyphenyl) cyclohexanone 西安瑞联新材料股份有限公司 2021-02-23 — — CN disclosed
CN-110028395-A A kind of preparation method of 4- (4- hydroxy phenyl) cyclohexanone 宁夏中星显示材料有限公司 2019-07-19 — — CN disclosed
CN-107674013-A Polycyclic compound, its preparation method, pharmaceutical composition and application 上海迪诺医药科技有限公司 2018-02-09 — — CN disclosed
US-9550793-B2 Spirocyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-01-24 — — US disclosed
US-9550793-B2 Spirocyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-01-24 — — US disclosed
WO-2008067257-A2 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-06-05 — — WO disclosed
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines ALTANA PHARMA AG (DE) 2007-08-30 — — US disclosed
EP-1805173-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS Altana Pharma AG (DE) 2007-07-11 — — EP disclosed
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 — — EP disclosed
WO-2005090346-A2 7, 8, 9, 10- TETRAHYDRO-IMIDAZO [2,1-A] ISOQUINOLINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS ALTANA PHARMA AG (DE) 2005-09-29 — — WO disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 — — US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 — — EP disclosed
EP-0035902-B1 1-(4-ARYL-CYCLOHEXYL)PIPERIDINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1984-10-31 — — EP disclosed
US-4329353-A ANTIEMETIC AND NEUROLEPTIC AGENTS JANSSEN PHARMACEUTICA, N.V. (BE) 1982-05-11 — — US disclosed
EP-0035902-A1 1-(4-Aryl-cyclohexyl)piperidine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1981-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203114-A1 7,8,9,10-Tetrahydro-Imidazo [2,1-A] Isochinolines GIPR, CCKBR, SLC10A2 MRGPRX4 571/4885ESR2 2633/4885HRH3 260/4885
US-20260055057-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 MRGPRX4 177/4885ESR2 1515/4885HRH3 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.